Profile data is unavailable for this security.
About the company
iBio, Inc. is a developer of next-generation biopharmaceuticals using its proprietary artificial intelligence (AI)-Driven Discovery Platform and FastPharming Manufacturing System. The Company is focusing its technologies on the research and development of novel products at its Drug Discovery Center in California. The Company through its FastPharming Manufacturing System and GlycaneeringSM Technologies develop its portfolio of proprietary biologic drug candidates. The Company operates through two segments: Biopharmaceuticals, and Bioprocessing. Its Biopharmaceuticals segment is engaged in large molecule discovery, development, and licensing activities. Its Bioprocessing segment is engaged in contract development and manufacturing services for recombinant proteins. Its pipeline includes IBIO-100, IBIO-101, IBIO-202, and IBIO-400. Its subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with GlycaneeringSM Development Services.
- Revenue in USD (TTM)2.00m
- Net income in USD-47.54m
- Incorporated2008
- Employees105.00
- LocationIbio Inc600 Madison Avenue, Suite 1601NEW YORK 10022-1737United StatesUSA
- Phone+1 (302) 355-0650
- Fax+1 (302) 356-1173
- Websitehttps://www.ibioinc.com/
More ▼
Mergers & acquisitions
| Acquired company | IBIO:ASQ since announced | Transaction value |
|---|---|---|
| Rubryc Therapeutics Inc | -75.88% | 6.00m |
Data delayed at least 15 minutes, as of Mar 22 2023 20:10 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rasna Therapeutics Inc | 0.00 | -561.79k | 29.25m | 0.00 | -- | -- | -- | -- | -0.0045 | -0.0045 | 0.00 | -0.01 | 0.00 | -- | -- | -- | -1,194.79 | -84.68 | -- | -486.62 | -- | -- | -- | -- | -- | -0.642 | -- | -- | -- | -- | 21.62 | -- | -- | -- |
| Lipocine Inc | 500.00k | -10.76m | 29.30m | 17.00 | -- | 0.8221 | -- | 58.59 | -0.1212 | -0.1212 | 0.0056 | 0.4026 | 0.0111 | -- | 3.05 | 29,411.77 | -23.90 | -38.07 | -26.01 | -45.95 | -- | -- | -2,151.73 | -330.89 | -- | -- | 0.00 | -- | -96.90 | -- | -1,595.88 | -- | -- | -- |
| Vistagen Therapeutics Inc | -363.90k | -63.71m | 29.35m | 32.00 | -- | 1.34 | -- | -- | -0.3083 | -0.3083 | -0.0018 | 0.0999 | -0.006 | -- | -- | -10,108.33 | -105.97 | -70.25 | -116.32 | -76.59 | -- | -- | -- | -5,704.43 | -- | -- | 0.0203 | -- | 1.78 | -2.37 | -15.09 | -- | -3.47 | -- |
| Zivo Bioscience Inc | 0.00 | -9.62m | 29.67m | 10.00 | -- | 19.47 | -- | -- | -1.04 | -1.04 | 0.00 | 0.1618 | 0.00 | -- | -- | 0.00 | -128.74 | -878.69 | -204.00 | -- | -- | -- | -- | -272,265.10 | -- | -819.80 | 0.1994 | -- | -100.00 | -- | -0.633 | -- | -- | -- |
| Sio Gene Therapies Inc | 0.00 | -50.27m | 30.07m | 12.00 | -- | 0.6148 | -- | -- | -0.6835 | -0.6835 | 0.00 | 0.6612 | 0.00 | -- | -- | 0.00 | -61.20 | -79.80 | -67.41 | -105.83 | -- | -- | -- | -- | -- | -3,350.67 | -- | -- | -- | -- | -121.70 | -- | 45.93 | -- |
| Arca Biopharma Inc | 0.00 | -9.93m | 30.41m | 5.00 | -- | 0.7296 | -- | -- | -0.6888 | -0.6888 | 0.00 | 2.89 | 0.00 | -- | -- | 0.00 | -20.26 | -35.30 | -21.26 | -37.94 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.63 | -- | -7.79 | -- |
| Ibio Inc | 2.00m | -47.54m | 30.43m | 105.00 | -- | 1.62 | -- | 15.18 | -5.30 | -8.85 | 0.2221 | 1.52 | 0.0225 | -- | 3.71 | 19,085.71 | -53.35 | -32.33 | -66.90 | -35.44 | 96.86 | -- | -2,372.46 | -1,396.73 | -- | -173.60 | 0.493 | -- | 0.5061 | 43.33 | -114.73 | -- | 48.82 | -- |
| PaxMedica Inc | 0.00 | -3.35m | 30.45m | 2.00 | -- | 12.48 | -- | -- | -0.2842 | -0.2842 | 0.00 | 0.2028 | 0.00 | -- | -- | 0.00 | -85.41 | -- | -- | -- | -- | -- | -- | -- | -- | -5,662.63 | 0.0615 | -- | -- | -- | -10.01 | -- | -- | -- |
| Mannatech Inc | 142.37m | 4.61m | 30.63m | 246.00 | 7.20 | 1.65 | 4.85 | 0.2152 | 2.27 | 2.27 | 70.12 | 9.93 | 2.45 | 2.15 | 691.10 | 578,723.60 | 7.92 | 4.13 | 16.89 | 7.88 | 78.00 | 79.08 | 3.24 | 1.67 | 0.7375 | 11.39 | 0.0257 | 56.85 | 5.52 | -2.39 | 57.20 | -- | -22.24 | 23.56 |
| Kala Pharmaceuticals Inc | 3.89m | -44.82m | 30.69m | 34.00 | -- | 1.36 | -- | 7.88 | -30.16 | -30.16 | 2.57 | 11.12 | 0.0344 | 0.5927 | 0.5009 | 114,470.60 | -39.62 | -54.04 | -54.95 | -63.22 | 34.22 | -- | -1,151.64 | -1,642.63 | 3.35 | -12.38 | 0.6935 | -- | -65.37 | -- | 68.57 | -- | -8.20 | -- |
| Axcella Health Inc | 0.00 | -76.08m | 30.80m | 59.00 | -- | -- | -- | -- | -1.66 | -1.66 | 0.00 | -0.1434 | 0.00 | -- | -- | 0.00 | -152.75 | -- | -218.17 | -- | -- | -- | -- | -- | -- | -26.51 | 1.43 | -- | -- | -- | -14.33 | -- | -- | -- |
| Correlate Infrastructure Partners Inc | 403.55k | -2.68m | 31.71m | 11.00 | -- | -- | -- | 78.57 | -0.0825 | -0.0825 | 0.007 | -0.0132 | 0.2844 | -- | -- | -- | -188.66 | -65.78 | -- | -- | 20.26 | 31.50 | -663.41 | -195.16 | 0.3337 | -2.29 | 1.82 | -- | -42.33 | -40.12 | 51.05 | -- | -- | -- |
| Eledon Pharmaceuticals Inc | 0.00 | -38.39m | 31.78m | 12.00 | -- | 0.2252 | -- | -- | -2.66 | -2.66 | 0.00 | 10.26 | 0.00 | -- | -- | 0.00 | -23.50 | -29.03 | -24.26 | -30.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.27 | -- | -- | -- |
| Freeline Therapeutics Holdings PLC (ADR) | 0.00 | -100.67m | 31.84m | 235.00 | -- | 0.4642 | -- | -- | -2.20 | -2.20 | 0.00 | 1.06 | 0.00 | -- | -- | 0.00 | -74.34 | -- | -87.37 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -45.75 | -- | -- | -- |
| Corvus Pharmaceuticals Inc | 0.00 | -40.73m | 31.89m | 28.00 | -- | 0.493 | -- | -- | -0.8746 | -0.8746 | 0.00 | 1.39 | 0.00 | -- | -- | 0.00 | -40.79 | -39.16 | -46.71 | -43.08 | -- | -- | -- | -- | -- | -4.44 | 0.00 | -- | -- | -- | -621.28 | -- | -70.40 | -- |
Data as of Mar 22 2023. Currency figures normalised to Ibio Inc's reporting currency: US Dollar USD
16.76%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Sabby Management LLCas of 31 Dec 2022 | 490.45k | 3.97% |
| The Vanguard Group, Inc.as of 31 Dec 2022 | 472.55k | 3.82% |
| Renaissance Technologies LLCas of 31 Dec 2022 | 381.60k | 3.09% |
| BlackRock Fund Advisorsas of 31 Dec 2022 | 269.24k | 2.18% |
| Susquehanna Financial Group LLLPas of 31 Dec 2022 | 134.85k | 1.09% |
| Geode Capital Management LLCas of 31 Dec 2022 | 76.29k | 0.62% |
| Dimensional Fund Advisors LPas of 31 Dec 2022 | 73.60k | 0.60% |
| Millennium Management LLCas of 31 Dec 2022 | 70.70k | 0.57% |
| Two Sigma Investments LPas of 31 Dec 2022 | 53.46k | 0.43% |
| Warberg Asset Management LLCas of 31 Dec 2022 | 50.00k | 0.40% |
More ▼
Data from 31 Dec 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
